The combination of 2‐deoxy‐d‐glucose (glycolysis inhibitors) and sorafenib (multikinase TKI, which inhibits CRAF, BRAF, VEGFR‐2, VEGFR‐3, PDGFR‐β, Flt3, c‐Kit, and p38α67) significantly suppresses the tumor growth of patient‐derived xenografts of NRASQ61 melanoma [344]. Here, BRAF is linked to neoplasm.